ArticleIndian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India2024
Chemoradiotherapy Induced Hearing Impairment in Head and Neck Malignancies.
Article in Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hearing impairment after treated by radio/chemotherapy for head and neck malignancies may compromise patients' communication and make them socially handicap. Thus, early detection of hearing loss may provide early access to hearing rehabilitation facilities and improve their quality of life. The present study was a 1-year prospective observational study conducted at tertiary care center, Jaipur, India. Total 90 patients treated with radio/chemo or combined therapy for head and neck malignancies were included in our study. Evaluation of type and degree of hearing loss with pure tone audiometry was done Pretreatment and Posttreatment at 1- and 6-months interval and data analyzed. Most common type of modality received by study population was chemoradiotherapy (41.1%) followed with radiotherapy (36.7%) and least common modality was chemotherapy (22.2%). We observed in our study that 50% of patients who received chemotherapy, 48.5% with radiotherapy and 81.1% patients who received concurrent chemoradiotherapy develops sensorineural hearing loss (SNHL) of various grade. Patients who were exposed with high dose of cisplatin developed more severe SNHL (44.44% grade 2, 44.44% grade 3 and 11.1% grade 0) when compared with low dose group of patients (81.8% grade 0 and 18.18% grade 2) and results were found significant (P value less than 0.05). Chemotherapy, with or without radiotherapy can cause hearing loss and it should be monitored to avoid permanent impairment Additionally, it can also guide the dosage to be delivered based on the patient's conditions, and if necessary, a more toxic drug can be replaced with a less toxic drug that is similarly efficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.